# RxSight, Inc.: financial statements, quarterly

RXST · Nasdaq · CIK 1111485 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rxst.md) · [Financials](/companies/rxst/financials.md) · [Filings](/companies/rxst/filings.md) · [Insiders](/companies/rxst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rxst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.2](/filings/0000950170-24-123368.md) | [28.6 d](/filings/0001193125-26-071775.md) | [29.5](/filings/0000950170-25-065683.md) | [34.9](/filings/0000950170-25-105070.md) | [35.3](/filings/0001193125-25-266986.md) | [40.2 d](/filings/0001193125-26-071775.md) | [37.9](/filings/0001193125-26-208921.md) | [33.6](/filings/0001193125-26-335153.md) | [30.3](/filings/0001193125-25-266986.md) | [32.6 d](/filings/0001193125-26-071775.md) | [30.9](/filings/0001193125-26-208921.md) | [27.2](/filings/0001193125-26-335153.md) |
| Cost of revenue | $m | [8.5](/filings/0000950170-24-123368.md) | [10.9 d](/filings/0001193125-26-071775.md) | [8.8](/filings/0000950170-25-065683.md) | [10.6](/filings/0000950170-25-105070.md) | [10.1](/filings/0001193125-25-266986.md) | [11.4 d](/filings/0001193125-26-071775.md) | [9.6](/filings/0001193125-26-208921.md) | [8.4](/filings/0001193125-26-335153.md) | [6.1](/filings/0001193125-25-266986.md) | [7.3 d](/filings/0001193125-26-071775.md) | [7.4](/filings/0001193125-26-208921.md) | [7.9](/filings/0001193125-26-335153.md) |
| Gross profit | $m | [13.7](/filings/0000950170-24-123368.md) | [17.7 d](/filings/0001193125-26-071775.md) | [20.7](/filings/0000950170-25-065683.md) | [24.3](/filings/0000950170-25-105070.md) | [25.2](/filings/0001193125-25-266986.md) | [28.8 d](/filings/0001193125-26-071775.md) | [28.3](/filings/0001193125-26-208921.md) | [25.2](/filings/0000950170-25-105070.md) | [24.2](/filings/0001193125-25-266986.md) | [25.3 d](/filings/0001193125-26-071775.md) | [23.5](/filings/0001193125-26-208921.md) | not reported |
| Research and development | $m | [7.1](/filings/0000950170-24-123368.md) | [7.3 d](/filings/0001193125-26-071775.md) | [8.0](/filings/0000950170-25-065683.md) | [8.3](/filings/0000950170-25-105070.md) | [8.8](/filings/0001193125-25-266986.md) | [9.2 d](/filings/0001193125-26-071775.md) | [10.4](/filings/0001193125-26-208921.md) | [10.2](/filings/0001193125-26-335153.md) | [9.1](/filings/0001193125-25-266986.md) | [8.9 d](/filings/0001193125-26-071775.md) | [9.5](/filings/0001193125-26-208921.md) | [9.2](/filings/0001193125-26-335153.md) |
| Selling, general and administrative | $m | [19.1](/filings/0000950170-24-123368.md) | [21.2 d](/filings/0001193125-26-071775.md) | [23.3](/filings/0000950170-25-065683.md) | [24.3](/filings/0000950170-25-105070.md) | [25.6](/filings/0001193125-25-266986.md) | [28.2 d](/filings/0001193125-26-071775.md) | [28.6](/filings/0001193125-26-208921.md) | [29.0](/filings/0001193125-26-335153.md) | [27.3](/filings/0001193125-25-266986.md) | [27.7 d](/filings/0001193125-26-071775.md) | [31.9](/filings/0001193125-26-208921.md) | [30.4](/filings/0001193125-26-335153.md) |
| Operating income | $m | [(12.5)](/filings/0000950170-24-123368.md) | [(10.9) d](/filings/0001193125-26-071775.md) | [(10.7)](/filings/0000950170-25-065683.md) | [(8.3)](/filings/0000950170-25-105070.md) | [(9.2)](/filings/0001193125-25-266986.md) | [(8.6) d](/filings/0001193125-26-071775.md) | [(10.7)](/filings/0001193125-26-208921.md) | [(14.0)](/filings/0001193125-26-335153.md) | [(12.2)](/filings/0001193125-25-266986.md) | [(11.3) d](/filings/0001193125-26-071775.md) | [(17.8)](/filings/0001193125-26-208921.md) | [(13.8)](/filings/0001193125-26-335153.md) |
| Interest expense | $m | [0.2](/filings/0000950170-24-123368.md) | [0.0 d](/filings/0001193125-26-071775.md) | [0.0](/filings/0000950170-25-065683.md) | [0.0](/filings/0000950170-25-105070.md) | [0.0](/filings/0001193125-25-266986.md) | [0.0 d](/filings/0001193125-26-071775.md) | [0.0](/filings/0001193125-26-208921.md) | [0.0](/filings/0001193125-26-335153.md) | [0.0](/filings/0001193125-25-266986.md) | [0.0 d](/filings/0001193125-26-071775.md) | [0.0](/filings/0001193125-26-208921.md) | [0.0](/filings/0001193125-26-335153.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-123368.md) | [(0.0) d](/filings/0001193125-26-071775.md) | [0.0](/filings/0000950170-25-065683.md) | [0.0](/filings/0000950170-25-105070.md) | [0.0](/filings/0001193125-25-266986.md) | [0.0 d](/filings/0001193125-26-071775.md) | [0.0](/filings/0001193125-26-208921.md) | [0.0](/filings/0001193125-26-335153.md) | [0.0](/filings/0001193125-25-266986.md) | [0.0 d](/filings/0001193125-26-071775.md) | [0.0](/filings/0001193125-26-208921.md) | [0.1](/filings/0001193125-26-335153.md) |
| Net income | $m | [(12.4)](/filings/0000950170-24-123368.md) | [(9.2) d](/filings/0001193125-26-071775.md) | [(9.1)](/filings/0001193125-25-266986.md) | [(6.1)](/filings/0001193125-25-266986.md) | [(6.3)](/filings/0001193125-25-266986.md) | [(5.9) d](/filings/0001193125-26-071775.md) | [(8.2)](/filings/0001193125-26-335153.md) | [(11.8)](/filings/0001193125-26-335153.md) | [(9.8)](/filings/0001193125-25-266986.md) | [(9.2) d](/filings/0001193125-26-071775.md) | [(15.9)](/filings/0001193125-26-335153.md) | [(12.1)](/filings/0001193125-26-335153.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0000950170-24-123368.md) | not reported | [(0.25)](/filings/0000950170-25-065683.md) | [(0.16)](/filings/0000950170-25-105070.md) | [(0.16)](/filings/0001193125-25-266986.md) | not reported | [(0.20)](/filings/0001193125-26-208921.md) | [(0.29)](/filings/0001193125-26-335153.md) | [(0.24)](/filings/0001193125-25-266986.md) | not reported | [(0.38)](/filings/0001193125-26-208921.md) | [(0.29)](/filings/0001193125-26-335153.md) |
| Basic EPS | $ per share | [(0.35)](/filings/0000950170-24-123368.md) | not reported | [(0.25)](/filings/0000950170-25-065683.md) | [(0.16)](/filings/0000950170-25-105070.md) | [(0.16)](/filings/0001193125-25-266986.md) | not reported | [(0.20)](/filings/0001193125-26-208921.md) | [(0.29)](/filings/0001193125-26-335153.md) | [(0.24)](/filings/0001193125-25-266986.md) | not reported | [(0.38)](/filings/0001193125-26-208921.md) | [(0.29)](/filings/0001193125-26-335153.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.9](/filings/0000950170-23-062099.md) | [9.7](/filings/0000950170-25-026681.md) | [32.6](/filings/0000950170-24-053566.md) | [24.4](/filings/0000950170-24-090770.md) | [16.7](/filings/0000950170-24-123368.md) | [16.7](/filings/0001193125-26-071775.md) | [28.0](/filings/0000950170-25-065683.md) | [40.4](/filings/0000950170-25-105070.md) | [29.6](/filings/0001193125-25-266986.md) | [19.9](/filings/0001193125-26-335153.md) | [17.6](/filings/0001193125-26-208921.md) | [13.4](/filings/0001193125-26-335153.md) |
| Current assets | $m | [168](/filings/0000950170-23-062099.md) | [168](/filings/0000950170-25-026681.md) | [169](/filings/0000950170-24-053566.md) | [281](/filings/0000950170-24-090770.md) | [287](/filings/0000950170-24-123368.md) | [294](/filings/0001193125-26-071775.md) | [288](/filings/0000950170-25-065683.md) | [284](/filings/0000950170-25-105070.md) | [284](/filings/0001193125-25-266986.md) | [287](/filings/0001193125-26-335153.md) | [279](/filings/0001193125-26-208921.md) | [327](/filings/0001193125-26-335153.md) |
| Total assets | $m | [182](/filings/0000950170-23-062099.md) | [183](/filings/0000950170-25-026681.md) | [183](/filings/0000950170-24-053566.md) | [305](/filings/0000950170-24-090770.md) | [310](/filings/0000950170-24-123368.md) | [319](/filings/0001193125-26-071775.md) | [313](/filings/0000950170-25-065683.md) | [309](/filings/0000950170-25-105070.md) | [309](/filings/0001193125-25-266986.md) | [312](/filings/0001193125-26-335153.md) | [304](/filings/0001193125-26-208921.md) | [353](/filings/0001193125-26-335153.md) |
| Current liabilities | $m | [18.9](/filings/0000950170-23-062099.md) | [20.9](/filings/0000950170-25-026681.md) | [18.3](/filings/0000950170-24-053566.md) | [19.6](/filings/0000950170-24-090770.md) | [22.6](/filings/0000950170-24-123368.md) | [25.9](/filings/0001193125-26-071775.md) | [22.7](/filings/0000950170-25-065683.md) | [20.4](/filings/0000950170-25-105070.md) | [22.3](/filings/0001193125-25-266986.md) | [26.3](/filings/0001193125-26-335153.md) | [27.4](/filings/0001193125-26-208921.md) | [80.4](/filings/0001193125-26-335153.md) |
| Total liabilities | $m | [20.4](/filings/0000950170-23-062099.md) | [22.2](/filings/0000950170-25-026681.md) | [19.2](/filings/0000950170-24-053566.md) | [30.3](/filings/0000950170-24-090770.md) | [33.2](/filings/0000950170-24-123368.md) | [37.3](/filings/0001193125-26-071775.md) | [33.7](/filings/0000950170-25-065683.md) | [31.0](/filings/0000950170-25-105070.md) | [32.6](/filings/0001193125-25-266986.md) | [36.1](/filings/0001193125-26-335153.md) | [36.7](/filings/0001193125-26-208921.md) | [89.4](/filings/0001193125-26-335153.md) |
| Long-term debt | $m | [0.0](/filings/0000950170-23-062099.md) | [0.0](/filings/0000950170-24-022073.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [161](/filings/0000950170-23-062099.md) | [160](/filings/0000950170-25-026681.md) | [164](/filings/0000950170-24-053566.md) | [275](/filings/0000950170-24-090770.md) | [277](/filings/0000950170-24-123368.md) | [281](/filings/0001193125-26-071775.md) | [279](/filings/0000950170-25-065683.md) | [278](/filings/0000950170-25-105070.md) | [276](/filings/0001193125-25-266986.md) | [276](/filings/0001193125-26-335153.md) | [267](/filings/0001193125-26-208921.md) | [263](/filings/0001193125-26-335153.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.0) d](/filings/0000950170-24-123368.md) | [(8.3) d](/filings/0001193125-26-071775.md) | [(9.3)](/filings/0000950170-25-065683.md) | [(4.0) d](/filings/0000950170-25-105070.md) | [0.7 d](/filings/0001193125-25-266986.md) | [(4.3) d](/filings/0001193125-26-071775.md) | [(8.8)](/filings/0001193125-26-208921.md) | [(4.4) d](/filings/0001193125-26-335153.md) | [(1.2) d](/filings/0001193125-25-266986.md) | [(1.1) d](/filings/0001193125-26-071775.md) | [(10.9)](/filings/0001193125-26-208921.md) | [(9.5) d](/filings/0001193125-26-335153.md) |
| Capital expenditure | $m | [0.7 d](/filings/0000950170-24-123368.md) | [1.6 d](/filings/0001193125-26-071775.md) | [2.0](/filings/0000950170-25-065683.md) | [1.5 d](/filings/0000950170-25-105070.md) | [1.1 d](/filings/0001193125-25-266986.md) | [0.8 d](/filings/0001193125-26-071775.md) | [0.6](/filings/0001193125-26-208921.md) | [1.5 d](/filings/0001193125-26-335153.md) | [0.6 d](/filings/0001193125-25-266986.md) | [1.1 d](/filings/0001193125-26-071775.md) | [0.8](/filings/0001193125-26-208921.md) | [2.0 d](/filings/0001193125-26-335153.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.7](/filings/0000950170-23-062099.md) | [31.6](/filings/0000950170-24-053566.md) | [34.5](/filings/0000950170-24-090770.md) | [35.7](/filings/0000950170-24-123368.md) | [36.8](/filings/0000950170-25-065683.md) | [38.5](/filings/0000950170-25-105070.md) | [39.8](/filings/0001193125-25-266986.md) | [40.5](/filings/0001193125-26-208921.md) | [40.7](/filings/0001193125-26-335153.md) | [41.0](/filings/0001193125-25-266986.md) | [41.3](/filings/0001193125-26-208921.md) | [41.5](/filings/0001193125-26-335153.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,593,256 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335153.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.